Mansanguan Suyanee, Charunwatthana Prakaykaew, Piyaphanee Watcharapong, Dechkhajorn Wilanee, Poolcharoen Akkapon, Mansanguan Chayasin
Bhumibol Adulyadej Hospital, Bangkok 10220, Thailand.
Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand.
Trop Med Infect Dis. 2022 Aug 19;7(8):196. doi: 10.3390/tropicalmed7080196.
This study focuses on cardiovascular manifestation, particularly myocarditis and pericarditis events, after BNT162b2 mRNA COVID-19 vaccine injection in Thai adolescents. This prospective cohort study enrolled students aged 13-18 years from two schools, who received the second dose of the BNT162b2 mRNA COVID-19 vaccine. Data including demographics, symptoms, vital signs, ECG, echocardiography, and cardiac enzymes were collected at baseline, Day 3, Day 7, and Day 14 (optional) using case record forms. We enrolled 314 participants; of these, 13 participants were lost to follow-up, leaving 301 participants for analysis. The most common cardiovascular signs and symptoms were tachycardia (7.64%), shortness of breath (6.64%), palpitation (4.32%), chest pain (4.32%), and hypertension (3.99%). One participant could have more than one sign and/or symptom. Seven participants (2.33%) exhibited at least one elevated cardiac biomarker or positive lab assessments. Cardiovascular manifestations were found in 29.24% of patients, ranging from tachycardia or palpitation to myopericarditis. Myopericarditis was confirmed in one patient after vaccination. Two patients had suspected pericarditis and four patients had suspected subclinical myocarditis. In conclusion, Cardiovascular manifestation in adolescents after BNT162b2 mRNA COVID-19 vaccination included tachycardia, palpitation, and myopericarditis. The clinical presentation of myopericarditis after vaccination was usually mild and temporary, with all cases fully recovering within 14 days. Hence, adolescents receiving mRNA vaccines should be monitored for cardiovascular side effects. Clinical Trial Registration: NCT05288231.
本研究聚焦于泰国青少年接种BNT162b2 mRNA新冠疫苗后的心血管表现，尤其是心肌炎和心包炎事件。这项前瞻性队列研究招募了来自两所学校的13至18岁学生，他们接种了第二剂BNT162b2 mRNA新冠疫苗。使用病例记录表在基线、第3天、第7天和第14天（可选）收集包括人口统计学、症状、生命体征、心电图、超声心动图和心肌酶的数据。我们招募了314名参与者；其中，13名参与者失访，剩余301名参与者进行分析。最常见的心血管体征和症状是心动过速（7.64%）、呼吸急促（6.64%）、心悸（4.32%）、胸痛（4.32%）和高血压（3.99%）。一名参与者可能有不止一种体征和/或症状。7名参与者（2.33%）表现出至少一种心脏生物标志物升高或实验室评估呈阳性。29.24%的患者出现心血管表现，范围从心动过速或心悸到心肌心包炎。一名患者在接种疫苗后被确诊为心肌心包炎。两名患者疑似心包炎，四名患者疑似亚临床心肌炎。总之，青少年接种BNT162b2 mRNA新冠疫苗后的心血管表现包括心动过速、心悸和心肌心包炎。接种疫苗后心肌心包炎的临床表现通常较轻且为暂时性，所有病例在14天内完全康复。因此，应监测接种mRNA疫苗的青少年的心血管副作用。临床试验注册编号：NCT05288231。
